Classification and Comparison of Early-onset and Late-onset Idiopathic Chronic Pancreatitis

Sponsor
Changhai Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03953937
Collaborator
(none)
1,633
1
240
6.8

Study Details

Study Description

Brief Summary

Classification of early-onset idiopathic chronic pancreatitis (EOICP) and late-onset idiopathic chronic pancreatitis (LOICP) was proposed based on bimodal distribution of age at onset of idiopathic chronic pancreatitis (ICP). However, studies of larger populations prove it may be normal distribution. Therefore, the aim of the study is to find what the distribution of age at onset of ICP is and whether the classification of EOICP and LOICP is meaningful.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Idiopathic chronic pancreatitis (ICP) patients admitted to the investigator's center from January 2000 to December 2013 were enrolled. Characteristics were compared between early-onset idiopathic chronic pancreatitis (EOICP) and late-onset idiopathic chronic pancreatitis (LOICP) patients. Cumulative rates of diabetes mellitus, steatorrhea, pancreatic stone, pancreatic pseudocyst (PPC), biliary stricture, and pancreatic cancer after the onset and the diagnosis of ICP were calculated, respectively. Different cut-off values for age at onset of ICP were set to classify EOICP and LOICP. Then differences of clinical courses between EOICP and LOICP were compared when classified by distinct cut-off values.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1633 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Classification and Comparison of Early-onset and Late-onset Idiopathic Chronic Pancreatitis
    Actual Study Start Date :
    Jan 1, 2000
    Anticipated Primary Completion Date :
    Dec 31, 2019
    Anticipated Study Completion Date :
    Dec 31, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    ICP cohort

    Patients with idiopathic pancreatitis

    Outcome Measures

    Primary Outcome Measures

    1. Distribution of age at onset of idiopathic chronic pancreatitis [December 31, 2013]

      Identify the distribution of age at onset of idiopathic chronic pancreatitis.

    2. Basic characteristics of early-onset idiopathic chronic pancreatitis and late-onset idiopathic chronic pancreatitis [December 31, 2013]

      Identify respective ratio of patients with male gender and patients with smoking history in early-onset idiopathic chronic pancreatitis and late-onset idiopathic chronic pancreatitis in traditional classification (traditional classification: age at onset of idiopathic chronic pancreatitis<35 years old as early-onset idiopathic chronic pancreatitis; age at onset of idiopathic chronic pancreatitis>35 years old as late-onset idiopathic chronic pancreatitis).

    Secondary Outcome Measures

    1. Basic characteristics of early-onset idiopathic chronic pancreatitis and late-onset idiopathic chronic pancreatitis with different cut-off values for age at onset of idiopathic chronic pancreatitis [August 31, 2019]

      Identify respective ratio of patients with male gender and patients with smoking history in early-onset idiopathic chronic pancreatitis and late-onset idiopathic chronic pancreatitis with different cut-off values for age at onset of idiopathic chronic pancreatitis.

    2. Diabetes mellitus [August 31, 2019]

      Evaluate incidence and cumulative incidence of endocrine insufficiency developed in early-onset and late-onset idiopathic chronic pancreatitis patients with different cut-off values for age at onset of idiopathic chronic pancreatitis.

    3. Steatorrhea [August 31, 2019]

      Evaluate incidence and cumulative incidence of exocrine insufficiency developed in early-onset and late-onset idiopathic chronic pancreatitis patients with different cut-off values for age at onset of idiopathic chronic pancreatitis.

    4. Pancreatic pseudocyst [August 31, 2019]

      Evaluate incidence and cumulative incidence of pancreatic pseudocyst developed in early-onset and late-onset idiopathic chronic pancreatitis patients with different cut-off values for age at onset of idiopathic chronic pancreatitis.

    5. Common bile duct stricture [August 31, 2019]

      Evaluate incidence and cumulative incidence of common bile duct stricture developed in early-onset and late-onset idiopathic chronic pancreatitis patients with different cut-off values for age at onset of idiopathic chronic pancreatitis.

    6. Pancreatic cancer [August 31, 2019]

      Evaluate incidence and cumulative incidence of pancreatic cancer developed in early-onset and late-onset idiopathic chronic pancreatitis patients with different cut-off values for age at onset of idiopathic chronic pancreatitis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients diagnosed with idiopathic chronic pancreatitis according to Asia-Pacific consensus
    Exclusion Criteria:
    • Pancreatic cancer diagnosed within 2 years after the diagnosis of chronic pancreatitis

    • Groove pancreatitis

    • Autoimmune pancreatitis

    • Chronic pancreatic patients with identified etiologies

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Changhai Hospital, Second Military Medical University Shanghai China 200433

    Sponsors and Collaborators

    • Changhai Hospital

    Investigators

    • Principal Investigator: Zhaoshen Li, Doctor, Changhai Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zhaoshen Li, Director of Gastroenterology Department, Changhai Hospital
    ClinicalTrials.gov Identifier:
    NCT03953937
    Other Study ID Numbers:
    • ICP-1
    First Posted:
    May 17, 2019
    Last Update Posted:
    Sep 12, 2019
    Last Verified:
    Sep 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 12, 2019